Patents by Inventor Richard David Carr

Richard David Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1 AGONIST AND CARDIOVASCULAR COMPLICATIONS
    Publication number: 20140206615
    Abstract: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 24, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Liselotte Bjerre Knudsen, Bidda Charlotte Rolin, Richard David Carr, Johan Selmer, Jens Larsen, Bodil Elbrond, Lars Bo Nielsen, Christina Christoffersen
  • GLP-1 Agonist and Cardiovascular Complications
    Publication number: 20130338071
    Abstract: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.
    Type: Application
    Filed: August 26, 2013
    Publication date: December 19, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Liselotte Bjerre Knudsen, Bidda Charlotte Rolin, Richard David Carr, Johan Selmer, Jens Larsen, Bodil Elbrond, Lars Bo Nielsen, Christina Christoffersen
  • GLP-I Agonist And Cardiovascular Complications
    Publication number: 20120295836
    Abstract: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.
    Type: Application
    Filed: April 4, 2012
    Publication date: November 22, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Liselotte Bjerre Knudsen, Bidda Charlotte Rolin, Richard David Carr, Johan Selmer, Jens Larsen, Bodil Elbrond, Lars Bo Nielsen, Christina Christoffersen
  • GLP-I Agonist And Cardiovascular Complications
    Publication number: 20110230409
    Abstract: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.
    Type: Application
    Filed: June 2, 2011
    Publication date: September 22, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Liselotte Bjerre Knudsen, Bidda Charlotte Rolin, Richard David Carr, Johan Selmer, Jens Larsen, Bodil Elbrond, Lars Bo Nielsen, Christina Christoffersen
  • GLP-I Agonist And Cardiovascular Complications
    Publication number: 20090215688
    Abstract: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.
    Type: Application
    Filed: June 5, 2008
    Publication date: August 27, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Liselotte Bjerre Knudsen, Bidda Charlotte Rolin, Richard David Carr, Johan Selmer, Jens Larsen, Bodil Elbrond, Lars Bo Nielsen, Christina Christoffersen
  • Inhibition of beta cell degeneration
    Patent number: 7064145
    Abstract: Methods for preventing beta cell degeneration, such as necrosis or apoptosis of beta cells in a subject, comprising administering a DPP-IV inhibitor to a subject in need thereof. The invention furthermore relates to a method for increasing the number and/or the size of beta cells. The invention also relates to a method for delaying the progression of Impaired Glucose Tolerance (IGT) to type 2 diabetes, as well as a method for delaying the progression of non-insulin demanding type 2 diabetes to insulin-demanding type 2 diabetes.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: June 20, 2006
    Assignee: Novo Nordisk A/S
    Inventor: Richard David Carr
  • Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
    Publication number: 20030236272
    Abstract: The present invention is related to a method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states comprising administering inhibitors of the enzymes NEP and DPP-IV to individuals suffering from one or more of those conditions. Inhibition of the activity of the two enzymes will potentiate the insulin releasing activity of endogenous GLP-1 and other DPP-IV substrates like GIP.
    Type: Application
    Filed: April 23, 2003
    Publication date: December 25, 2003
    Inventor: Richard David Carr
  • Inhibition of beta cell degeneration
    Publication number: 20030220251
    Abstract: This invention relates to a method for modulating, inhibiting or decreasing or preventing beta cell degeneration, loss of beta cell function, beta cell dysfunction, and/or death of beta cells, such as necrosis or apoptosis of beta cells in a subject comprising administering a GLP-1 agonist to said subject.
    Type: Application
    Filed: February 24, 2003
    Publication date: November 27, 2003
    Inventors: Liselotte Bjerre Knudsen, Carsten Foged Godtfredsen, Jacob Sten Petersen, Richard David Carr
  • GLP-1 agonist and cardiovascular complications
    Publication number: 20030220255
    Abstract: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.
    Type: Application
    Filed: April 3, 2003
    Publication date: November 27, 2003
    Inventors: Liselotte Bjerre Knudsen, Bidda Charlotte Rolin, Richard David Carr, Johan Selmer, Jens Larsen, Bodil Elbrond, Lars Bo Nielsen, Christina Christoffersen
  • Inhibition of beta cell degeneration
    Patent number: 6569832
    Abstract: This invention relates to a method for modulating, inhibiting or decreasing or preventing beta cell degeneration, loss of beta cell function, beta cell dysfunction, and/or death of beta cells, such as necrosis or apoptosis of beta cells in a subject comprising administering a GLP-1 agonist to said subject.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: May 27, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Liselotte Bjerre Knudsen, Carsten Foged Godtfredsen, Jacob Sten Petersen, Richard David Carr, Søren Bregenholt
  • Inhibition of beta cell degeneration
    Publication number: 20010025023
    Abstract: Methods for preventing beta cell degeneration, such as necrosis or apoptosis of beta cells in a subject, comprising administering a DPP-IV inhibitor to a subject in need thereof. The invention furthermore relates to a method for increasing the number and/or the size of beta cells. The invention also relates to a method for delaying the progression of Impaired Glucose Tolerance (IGT) to type 2 diabetes, as well as a method for delaying the progression of non-insulin demanding type 2 diabetes to insulin-demanding type 2 diabetes.
    Type: Application
    Filed: February 21, 2001
    Publication date: September 27, 2001
    Inventor: Richard David Carr